Lipo/TK-CDN/TPP/Y6 nanoparticles inhibit cutaneous melanoma formation.

Autor: Xiao A; Department of Dermatology and Venereology, Dejiang County People's Hospital, Affiliated to Zunyi Medical University, Dejiang, China., Yin L; Department of Pathology, Dejiang County People's Hospital, Affiliated to Zunyi Medical University, Dejiang, China., Chen T; Department of Clinical Medicine, Dejiang County People's Hospital, Affiliated to Zunyi Medical University, Dejiang, China., Qian H; Department of Endocrinology, Dejiang County People's Hospital, Affiliated to Zunyi Medical University, Dejiang, China.
Jazyk: angličtina
Zdroj: Journal of drug targeting [J Drug Target] 2024 Sep; Vol. 32 (8), pp. 931-940. Date of Electronic Publication: 2024 Jun 17.
DOI: 10.1080/1061186X.2024.2365243
Abstrakt: Stimulation of the innate immune stimulator of interferon genes (STING) pathway has been shown to boost anti-tumour immunity. Nevertheless, the systemic delivery of STING agonists to the tumour presents challenges. Therefore, we designed a cyclic dinucleotide (CDN)-based drug delivery system (DDS) combined photothermal therapy (PTT)/photodynamic therapy (PDT)/immunotherapy for cutaneous melanoma. We coencapsulated a reactive oxygen species (ROS)-responsive prodrug thioketone-linked CDN (TK-CDN), and photoresponsive agents chlorin E6 (Y6) within mitochondria-targeting reagent triphenylphosphonium (TPP)-modified liposomes (Lipo/TK-CDN/TPP/Y6). Lipo/TK-CDN/TPP/Y6 exhibited a photothermal effect similar to Y6, along with a superior cellular uptake rate. Upon endocytosis by B16F10 cells, Lipo/TK-CDN/TPP/Y6 generated large amounts of ROS under laser irradiation for PDT. Mice bearing B16F10 tumours were intravenously injected with Lipo/TK-CDN/TPP/Y6 and exposed to irradiation, resulting in a substantial inhibition of tumour growth. Exploration of the mechanism of anti-tumour action showed that Lipo/TK-CDN/TPP/Y6 had a stronger stimulation of STING activation and anti-tumour immune cell infiltration compared to other groups. Hence, the Lipo/TK-CDN/TPP/Y6 nanoparticles offer great potential as a DDS for targeted and on-demand drug release at tumour sites. These nanoparticles exhibit promise as a candidate for precise and controllable combination therapy in the treatment of tumours.
Databáze: MEDLINE